I was reading the cover story in Time Magazine this week about the filovirus outbreaks tearing through the Democratic Republic of the Congo and Uganda, and one line stopped me. The gist of it was this: we now possess more genomic tools, more monoclonal antibodies, more vaccine science than at any point in human history, and yet we keep producing outbreaks that rival or exceed the worst of the past. This tells you something important. This is not a science problem.
Science has already handed us the ability to master much of what is killing people right now. What we are failing at is something else entirely. We are failing at implementation. We have the toolbox. We are simply not opening it, or not opening it in time, or in some cases deliberately locking it shut. That single idea runs through nearly every story worth discussing this week.
Ebola in the DRC: an outbreak outrunning the science
The current Ebola outbreak in the DRC is, by most measures, the best-resourced Ebola response on record. We understand this virus better than almost any other hemorrhagic fever. We have vaccines, therapeutics, diagnostics, and decades of hard-won field experience. And the outbreak is outrunning all of it.
The counts now sit at more than 1,500 cases with 500+ deaths, and the virus has reached a fourth province. That matters geographically, because this province borders both the Central African Republic and South Sudan, which means the outbreak now carries a real risk of spilling across international lines and pulling additional countries into the response.
The most troubling signal is buried in the epidemiology. The majority of confirmed cases cannot be linked to a known contact. In outbreak terms, that is a flashing red light. It means there are chains of transmission we simply cannot see, and it means diagnosed patients have gone missing from the system entirely. Unseen transmission and vanished cases translate directly into more spread and a fire that is far harder to extinguish.
Meanwhile the people doing the most dangerous work on the planet, the burial teams, are facing violence from communities that do not want their ceremonies disrupted or their dead handled by strangers in protective gear. Bodies carry enormous viral loads around the time of death, so these rituals are genuine transmission events, and the teams trying to make them safe are being met with hostility. Ebola treatment units are being attacked. People are being killed inside them. This is no longer only a virological problem. It is a failed-state problem, unfolding in a place where the rule of law and respect for individual rights have collapsed, and the virus is exploiting that vacuum as efficiently as it exploits a susceptible host.
The damage does not stay in the health sector. Economic modeling now puts the worst-case scenario in the range of several billion dollars, with GDP losses that will push more people in an already impoverished region below the poverty line. This is what epidemics actually do. They cascade. They reach into every corner of ordinary life, because an economy, at its base, is nothing more than the sum of people's lives.
There is one genuine bright spot. A clinical trial has begun enrolling patients, testing remdesivir in combination with a monoclonal antibody from Mapp Biopharmaceutical. It will take time to get a meaningful readout, but enrollment of that first patient is a milestone in itself. Still, the bottom line is stark. We are watching an outbreak that is costing more, in both lives and dollars, than the available science should ever allow. That gap between what we know and what is happening on the ground is the implementation problem in its purest form.
The vaccine fights in Washington
If the DRC shows you implementation failure through state collapse, Washington shows you something more deliberate. Here we have a federal health department at odds with its own evidence, with the courts, with practicing physicians, and increasingly with the public, which is at least pushing back. That pushback is a good thing.
Several developments this week are worth understanding together. The Second Circuit affirmed that New York schools can require vaccination as a condition of entry. I want to be precise about what this is and is not. This is not a mandate in the coercive sense that the word is often thrown around. A public school system setting its own safety-based entry requirements is no different from a public transit system setting its own safety rules. The case will likely be appealed to the Supreme Court, and I cannot predict where it ends, but the underlying principle, that public institutions may be run safely, is sound.
On CBS's Face the Nation, Deborah Houry, a former top CDC physician who heroically resigned in protest after Susan Monarez was unjustly fired, said plainly what many of us have concluded, that RFK Jr.'s position is unmoored from science and from reality. He holds what amounts to a fixed, quasi-religious belief about vaccines. No quantity of evidence reaches him, because his conviction is not built on evidence in the first place. It rests on an emotional pull, on the myth that the unvaccinated state is somehow more natural. When a belief is not formed by evidence, it cannot be dislodged by evidence. He is, functionally, impervious to it.
Then there is Senator Cassidy, the physician who cast one of the deciding votes to advance RFK Jr.'s nomination and who now complains that RFK Jr. broke his promises. I find this difficult to take seriously. Everyone understood that these promises would be broken, because a promise requires a commitment to truth, and truth requires correspondence to reality. A man who has spent decades demonstrating his indifference to reality cannot make a meaningful promise. His words are words, no more binding than a parrot's. Cassidy's attempt to justify what was plainly a political calculation deserves no sympathy.
The news is not all grim. In Florida, a bill that would have made it easier to obtain vaccine exemptions for school, effectively loosening entry requirements, appears to be dead in the state legislature. This is encouraging, and it reflects something the noise often obscures: a large bipartisan majority of Americans continues to support vaccine entry requirements for schools.
That brings me to a group I read about this week and had not seen named so clearly before, the malleable middle. These are people who hold a few vaccine myths in their heads but remain genuinely persuadable. I do not pretend to know the perfect method for reaching them. Some suggest motivational interviewing, an effort to understand what is actually driving the hesitation. What I do know is that this is precisely the population the anti-vaccine movement targets hardest with disinformation, which means the window to reach the malleable middle may be closing.
For all the drama playing out in courtrooms and on cable news, one thing has not changed. The underlying science, that vaccines save lives, that they are among the greatest innovations the human mind has ever produced, is exactly where it was. Washington cannot move it.
Marburg, layered onto Uganda
Now to Marburg, which is a filovirus in the same family as Ebola. It has no medical countermeasures, a distinction it shares with the Bundibugyo strain of Ebola, and it is being layered onto an already active Ebola response in Uganda.
There is at least one confirmed case, in an 18-month-old child, with a possible second case that remains nebulous. The age of that first case is what concerns me most. A toddler is almost never the index case in a Marburg outbreak. Someone had to acquire the virus first, likely through contact with a bat or with bush meat, which means there is an unidentified chain of transmission somewhere upstream that we have not yet found.
The reassuring part is that Uganda is a country that has handled Marburg before and is generally well equipped for it. It has largely contained its concurrent Ebola outbreak at around 20 cases. So the questions I will be watching over the next week are straightforward. What is the true case count? How heavy will the response burden be? For now, this is one more reminder that these filoviruses keep coming at our species, and that competence in the response is the variable that determines the outcome.
Measles, from Bangladesh to Pennsylvania
Measles is where the implementation problem becomes almost mathematical. Consider Bangladesh. One year ago, in 2025, the country recorded 125 measles cases. It now has more than 100,000. Nothing about the virus changed. There was no biological shift, no new variant. What happened was an administrative collapse: a lapsed immunization program under an interim government and a breakdown in coordination with UN agencies. That is all it took to move from 125 to six figures.
The same principle operates everywhere. When population immunity drops, measles takes the opening, and it does not care whether that opening is in Dhaka or in Pennsylvania. Pennsylvania is having a banner year for measles, and in a recent interview the state's Secretary of Health wished aloud for a magic bullet. I understand the sentiment, but I want to correct the framing, because it matters. There already is a bullet. It is the vaccine. But, it is not magic. It is the product of a reasoning mind applying science to a problem. We do not need magic bullets. We need scientific ones, and they already exist.
In Delaware County, adjacent to venues hosting World Cup matches, wastewater surveillance has detected measles at least twice, even though no cases have been formally reported there. That is exactly why wastewater monitoring is so valuable. It tells you the virus is circulating before the case counts catch up, and it strongly suggests there are more infections in Pennsylvania than the official numbers show.
The deeper truth is that measles is the default. It will always reassert itself unless people take deliberate, sustained action to prevent it. Elimination, which the United States is now at real risk of losing, is not a resting state you achieve once and keep. It is a constant achievement that has to be earned every single year through active vaccination. A passive response guarantees the disease returns. Bangladesh going from 125 to more than 100,000 cases in twelve months, with hospitals inundated and parents fearing for their children, is what implementation failure looks like.
Ticks, Lyme, and a vaccine worth wanting
There is genuine promise in tick-borne disease right now, along with the usual frustrations. This has been a banner year for tick bites, with emergency department visits running very high, and much of the coverage has centered on a new Pfizer Lyme vaccine in the pipeline.
That vaccine is not yet approved. It is in late clinical development, with roughly 75 percent efficacy, and it requires multiple doses. It is not perfect, but it is meaningfully better than nothing, and it arrives in the long shadow of a first-generation Lyme vaccine that was pulled from the market years ago over lawsuit threats and low uptake. That history matters, because uptake is shaping up to be the central challenge again. A Kaiser Family Foundation piece interviewed hunters, one of the highest-risk groups for Lyme, and found real hesitancy among them. When people who understand the threat intimately are still hesitant, whether because of the multiple-dose schedule or the imperfect efficacy, it tells you how much work remains.
Encouragingly, the vaccine is not the only countermeasure in development. There are monoclonal antibodies that could be given at the start of tick season to provide a protective window, and there are pills under study that render your blood toxic to a feeding tick, killing it before it can transmit the Lyme bacterium, which typically takes a day or two of attachment to accomplish.
A few points about tick-borne disease deserve wider appreciation. First, it is a year-round threat. You are hearing about it now because cases are up, but ticks bite in winter too. A study in Illinois found tick-borne illness occurring throughout the year, with the single exception of babesiosis, which is absent in the colder months. Second, we should pay more attention to Powassan virus, a tick-borne encephalitis, meaning it inflames the brain, spread by the same ticks that carry Lyme. In 2015 there were seven cases. In 2025 there were 76. Whether that reflects more true infections or better diagnostics is unclear, but it belongs on your radar.
Finally, a word about post-treatment Lyme disorder, what many call chronic Lyme disease. It is a real symptom complex, and I do not dismiss the suffering of the people who live with it. But multiple studies show it is not caused by a persistent bacterial infection, which means prolonged courses of antibiotics will not help. Around these patients has grown a profitable, evidence-free cottage industry offering treatments like hyperbaric oxygen and radiofrequency devices meant to blast away bacteria that are not there. Now RFK Jr. has waded in with a Lyme disease initiative, and I expect he will lend legitimacy to exactly these practitioners. The reason is the same one we keep returning to. He does not care about science or about reality, because he does not know what those things are.
A game worth playing
I will end the roundup with a story I genuinely enjoyed. NPR reported on a game out of Nigeria, a takeoff on Chutes and Ladders called Schisto and Ladders. Schisto is schistosomiasis, a parasitic and badly neglected tropical disease that people acquire from contaminated water, with snails serving as the intermediate host. The game teaches children how to protect themselves: stay out of contaminated water, take antiparasitic medication when it is warranted, and clear the tall grass around water sources where those snails thrive. It is a clever piece of public health, and honestly, I would like to get my hands on a copy.
The question that remains
As I close, I want to make the common thread explicit, because it is easy to miss when each of these stories is treated in isolation. The DRC is not struggling with Ebola because no one understands Ebola. Bangladesh did not suffer a measles catastrophe because the virus changed. Uganda's Marburg response is not waiting on some elusive scientific breakthrough. And the fight over vaccines in the United States is not, at its core, a dispute about what the evidence shows.
The science exists. The technologies exist. What determines the outcome of an outbreak is whether a society can identify the threat, build the institutions, maintain the trust, deploy the resources, and apply what it already knows. That is an implementation problem, and infectious disease keeps teaching us the same lesson: knowledge alone is never enough. Human reason produces the vaccines, the diagnostics, the treatments, and the public health systems, but those tools only matter when people choose to pick them up. You can hold the finest toolbox in history, and if you do not know how to use it, or refuse to use it, or lock it away where no one can reach it, you are no better off than our ancestors who had nothing at all.
The microbes will never stop working. The only open question is whether we will.
